Skip to main content

Table 1 Clinicopathological factors associated with DFS in ICC patients

From: Should lymphadenectomy performed routinely in patients with primary intrahepatic cholangiocarcinoma undergoing curative hepatectomy? A retrospective cohort study with propensity-score matching analysis

Variables

Univariate analysis

Multivariate analysis

P value

HR (95% CI)

P value

Age (65)

0.645

 

0.585

Gender (male)

0.007

 

0.225

HBsAg positive

0.006

 

0.418

Child-Pugh Class (A/B)

0.910

 

0.875

AST31 IU/L

< 0.001

1.615 (1.192–2.188)

0.002

CA-19936.2 U/mL

0.352

 

0.324

Tumor diameter 5 cm

< 0.001

1.679 (1.211–2.327)

0.002

Multifocal lesions

< 0.001

1.514 (1.120–2.048)

0.007

Major hepatectomy

0.175

 

0.482

Lymphadenectomy

0.304

 

0.920

Tumor differentiation (Poor)

0.004

 

0.122

Macrovascular invasion

< 0.001

1.564 (1.034–2.364)

0.034

Microvascular invasion

< 0.001

 

0.063

Perineural invasion

0.205

1.793 (1.004–3.204)

0.048

Periductal invasion

0.277

2.127 (1.041–4.347)

0.038

Margin positive

0.671

 

0.663

Lymph node metastasis

0.024

 

0.143

Pathological cirrhosis

0.010

 

0.349

Antiviral therapy

0.083

 

0.631

Adjuvant therapy

< 0.001

0.602 (0.447–0.810)

0.001

  1. AST alanine aminotransferase, CA19–9 carbohydrate antigen 19–9, DFS disease-free survival, HBsAg hepatitis B virus surface antigen, HR hazard ratio, CI confidence interval, ICC intrahepatic cholangiocarcinoma